Wolfgang Miesbach/LinkedIn
Dec 7, 2025, 16:21
Wolfgang Miesbach: Beyond Immunosuppression – Two new ways to treat ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Beyond Immunosuppression: Two new ways to treat ITP. David Kuter gave a great presentation at ASH 2025:
- Increase Platelet Production
The latest TPO receptor agonist, hetrombopag, now in Phase 3 trials, offers a direct pathway to boost platelet synthesis—moving away from suppression toward restoration. - Decrease Platelet Destruction
A diverse arsenal of targeted therapies can redefineour strategy:
– Anti-CD38 antibodies (daratumumab, mezagitamab)
– BAFF/BAFF-R inhibitors
– FcRn inhibitors (efgartigimod)
– BTK inhibitors (rilzabrutinib, orelabrutinib)
– Complement inhibitors + immunomodulatory approaches
– T-cell engagers and CAR-T therapies
ITP is now recognized as a disorder of both reduced production AND increased destruction—this understanding drives treatment selection toward complete remission, not just disease suppression.”
Find the full coverage of ASH25 in Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention